Upregulation of CD11b on Eosinophils in Aspirin Induced Asthma  by Isogai, Sumito et al.
Allergology International Vol 62, No3, 2013 www.jsaweb.jp 367
Upregulation of CD11b on Eosinophils
in Aspirin Induced Asthma
Sumito Isogai1, Masamichi Hayashi1, Naoki Yamamoto2, Mariko Morishita1, Tomoyuki Minezawa1,
Takuya Okamura1, Tami Hoshino1, Mitsushi Okazawa1 and Kazuyoshi Imaizumi1
ABSTRACT
Background: Although a challenge test using non-steroidal anti-inflammatory drugs (NSAIDs) is crucial for di-
agnosis of aspirin-induced asthma (AIA), it also has drawbacks in terms of possible side effects. Therefore, al-
ternative in-vitro diagnostic methods for AIA are awaited.
Methods: Nineteen stable non-AIA patients (9 males and 10 females; mean age, 49.4 ± 4.8 years), and
20 AIA patients (9 males and 11 females; mean age, 51.1 ± 4.8 years) were enrolled in this study. CD11b and
CD16 expressions on the peripheral-blood granulocytes after administration of aspirin and different concentra-
tions of PGE2 in vitro were examined using flowcytometry.
Results: Aspirin induced a significant increase in CD11b expression on eosinophils (CD16 negative granulo-
cytes) in 19 AIA patients and one non-AIA patient. Increase in CD11b expression on eosinophils by aspirin ad-
ministration was suppressed by PGE2 in a dose-dependent manner.
Conclusions: The measurement of CD11b expression on peripheral-blood eosinophils showed very high
sensitivity and specificity of (-95%) in diagnosing AIA. Although this method requires laboratory facilities for
flowcytometry, it may be very useful in diagnosis of AIA without side effects. In addition, PGE2 may be involved
in regulation of CD11b expression on eosinophils by aspirin administration.
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INTRODUCTION
In patients with AIA, asthma attacks are induced by
almost all NSAIDs having aspirin-like effects. Cy-
clooxygenase (COX) inhibition, which is a pharma-
cological action common to these NSAIDs, is consid-
ered to trigger this hypersensitivity reaction to aspi-
rin. In other words, AIA is thought to accompany
some abnormalities in the biological reaction associ-
ated with the pathway of arachidonic acid metabolism
or arachidonic acid metabolite, and such abnormali-
ties become obvious after administration of NSAIDs
and manifest as hypersensitivity reactions.
Although a challenge test using NSAIDs is essen-
tial for the definitive diagnosis of AIA, it has problems
both in terms of the diagnostic sensitivity and speci-
ficity and is associated with risks. Therefore, meth-
ods for in vitro diagnosis of AIA have been sought.
Several attempts have been made to develop in vitro
diagnosis methods for AIA, and approaches based
on peptide leukotriene (pLT) production, 15-hydroxy-
eicosatetraenoic (HETE) production,1,2 and lipoxin
production3 in peripheral blood polymorphonuclear
leukocytes (PMNs) as indicators have been exam-
ined. However, adequate follow-up and verification
have not been conducted, and their usefulness re-
mains questionable.
Eosinophils are inflammatory cells that play central
roles in the onset and pathology of AIA and are
known to be activated by the administration of aspirin
in AIA patients.4 If a reaction specific to AIA could be
detected at the level of the peripheral blood eosino-
phils, it may be useful for the diagnosis and clinical
research of AIA. Therefore, the potential usefulness
of a method using the adhesion molecule CD11b ex-
pressed on the cell surface of eosinophils as a marker
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Table　1　Patient characteristics of the patients in this study
AIA non-AIA
n 20 19
Sex (M/F) 9/11 9/10 n.s.
Age (mean [SD]) 51.1 (4.8) 49.4 (4.8) n.s.
Atopic (YES/NO) 7/13 8/11 n.s.
WBC (/mm3: mean [SD]) 6400 (1300) 6800 (1900) n.s.
Eosinophil (%: mean [SD]) 8.3 (5.2) 6.7 (5.0) n.s.
Severity (mild/moderate) 7/13 8/11 n.s.
Therapy
ICS (μg: mean [SD]) 350 (171) 310 (112) n.s.
LABA (n)  6  5 n.s.
Theophylline (n)  7  9 n.s.
LTRA (n) 11  7 n.s.
n.s., not signifi cant; ICS, inhaled corticosteroid; LABA, long act-
ing beta agonist; LTRA, leukotriene receptor antagonist.
for the in vitro diagnosis of AIA was examined in this
study.
METHODS
SUBJECTS
For the basic examination, 8 non-AIA patients (3
males and 5 females; mean age, 41.3 ± 16.0 years)
and 8 AIA patients (4 males and 4 females; mean age,
42.9 ± 10.1 years) who were being treated at the out-
patient unit of our hospital and whose symptoms
were stable (mild or moderate by GINA [Global In-
itiative for Asthma] classification) at the time of en-
rollment in the study were selected as the subjects.
The characteristics and background of AIA and non-
AIA patients who participated in this study were
shown in Table 1. All patients in this study were diag-
nosed as asthma because of common asthmatic
symptoms and pulmonary function indicating the re-
versibility of airflow limitation, i.e.; 1) Post-
bronchodilator improvement of 12% and 200 ml in
forced expiratory volume in 1 second (FEV1.0) from
the baseline, or 2) >20% increase in FEV1.0 following 2
weeks of treatment with inhaled or systemic corti-
costeroids. For the diagnosis of AIA, we used inhala-
tion provocation test. Increasing doses of tolmetin
and sulpyrine in geometric progression (tolmetin;
0.05, 0.5, 5.0, 50 mgml and sulpyrine; 1.0, 10, 100
mgml) were administered patients by inhalation
from a dosimeter-controlled jet nebulizer. The provo-
cation test was considered positive and stopped when
FEV1.0 had fallen >20% from the post-saline baseline
value. For examination of the in vitro diagnosis
method, 19 non-AIA patients (9 males and 10 females;
mean age, 49.4 ± 4.8 years) and 20 AIA patients (9
males and 11 females; mean age, 51.1 ± 4.8 years)
who were being treated at the outpatient unit of our
hospital and whose symptoms were stable at the time
of enrollment in this study were selected as the sub-
jects.
The significance of this study was explained to all
the subjects, and informed consent was obtained
from each of them. Then, basic pulmonary function
tests and general hematology tests were conducted,
and peripheral venous blood samples were collected.
All the subjects were subjected to tolmetin and
sulpyrine inhalation challenge tests for diagnosis of
hypersensitivity to NSAIDs. Patients who were as-
sessed as showing positive results in these inhalation
challenge tests and who also had a history of NSAID-
induced asthma attacks were regarded as having
AIA. Patients who showed negative on all these tests
were regarded as non-AIA.
Isolation of Peripheral Blood Eosinophils
Approximately 20 ml of blood was collected from a
peripheral vein of the target patients, and PMNs were
isolated from the blood by the specific gravity centri-
fuge method using mono-poly resolving medium
(Dainippon Pharmaceutical, Osaka, Japan). The cells
were washed with phosphate-buffered saline (PBS),
and the cell count was adjusted to 2 × 106mL with
RPMI1640 culture solution containing 10% fetal bo-
vine serum (FBS) (Sigma, St Louis, MO, USA) (Fig.
1).
Measurement of CD11b Expression
The suspension of isolated PMNs was stained for 45
minutes with fluorescein isothiocyanate (FITC)-
labeled CD11b monoclonal antibody and phyco-
erythrine (PE)-labeled CD16 monoclonal antibody
while being kept cool with ice. Then, the sample was
immobilized with 1% paraformaldehyde. Thereafter,
the eosinophil fraction (CD16-negative) and neutro-
phil fraction (CD16-positive) were separated using
flowcytometer (FACScan, Becton Dickinson, NJ,
USA) based on the presenceabsence of CD16 ex-
pression, and the CD11b expression level was deter-
mined by mean fluorescence intensity (MFI). To in-
vestigate the effect of aspirin, aspirin was added to a
suspension of the isolated PMNs at a concentration of
10−4 M-10−7 M, followed by double stain for CD11b
and CD16. Furthermore, the effect of addition of
prostaglandin E2 (PGE2) (10−7 M-10−5 M) on the
aspirin-induced change of CD11b expression level
was also examined. A sample of the non-stimulated
cell suspension to which the vehicle alone was added
was used as the control.
Ethical Considerations
As described above, the subjects were enrolled after
the objectives, method, and significance of the study
had been clearly explained and informed consent had
been obtained and this study was approved by the
ethics committee of Fujita Health University. The
sulpyrine and tolmetin inhalation challenge tests
were conducted to diagnose hypersensitivity to
CD11b for Diagnosis of AIA
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Fig.　1　A scheme of experimental procedures. Approximately 20 ml of peripheral 
blood was collected from each patient, and polymorphonuclear leukocytes (PMNs) 
were isolated by the specifi c gravity centrifuge method. Aspirin with or without 
PGE2 was added to a suspension of the isolated PMNs. After centrifugation 
followed by re-suspension with PBS, the sample was stained with FITC-labeled 
anti-CD11b monoclonal antibody and PE-labeled anti-CD16 monoclonal antibody.
Centrifugation
Ficoll-hypaque liquid
Incubate 30 min 37°C
2 × 106 cell/ml
RPMI1640 with 10% FBS
Polymorphonuclear cell
layer
FITC-labeled anti-CD11b Ab
PE-labeled anti CD16 Ab
On ice 45 min
Aspirin (10−4-10−7 M)
With or without PGE2
NSAIDs. These tests are routinely conducted in pa-
tients with bronchial asthma at our department, and
therefore, were considered as being within the scope
of routine clinical practice.
Statistics
All but a few figures were expressed as mean ± S.E.
Concerning the results of measurements by flowcy-
tometry, the value in the control was regarded as
100%, and the change rates were calculated according
to the equation; change rate = (target MFI - control
MFI)control MFI. Mann-Whitney’s U test was used
for the statistical processing, and the level of signifi-
cance was set at p < 0.05.
RESULTS
COMPARISON OF THE BASIC EXPRESSION
LEVELS OF EOSINOPHIL CD11b IN THE NON-
STIMULATED STATE
Flowcytometric analysis of PMNs with CD16 anti-
body clearly demonstrated two distinct cell popula-
tions (neutrophils as CD16-positive and eosinophils
as CD16-negative) (Fig. 2a). Thus, we could identify
the eosinophils from PMNs by gating for CD16 nega-
tive cell population (Fig. 2b) and used them in the fol-
lowing experiments. In this study, we analyzed the
surface expression of CD11b quantitatively by fluo-
rescence intensity. MFI representing CD11b expres-
sion in the non-stimulated state was 147.3 ± 12.1 in
the non-AIA group and 130.4 ± 4.7 in the AIA group;
the difference between the two groups was not sig-
nificant (Fig. 3).
EFFECTS OF ASPIRIN ADDITION ON THE CD11b
EXPRESSION LEVEL
We investigated the effect of aspirin addition on the
CD11b surface expression on eosinophils evaluated
quantitatively by fluorescence intensity. The change
of CD11b expression level from the baseline was -5.7
± 3.2% in the non-AIA group and 6.1 ± 3.1% in the AIA
group after addition of 10−7 M aspirin, -3.5 ± 2.2% in
the non-AIA group and 9.9 ± 3.1% in the AIA group af-
ter addition of 10−6 M aspirin, -1.2 ± 2.2% in the non-
AIA group and 7.3 ± 3.1% in the AIA group after addi-
tion of 10−5 M aspirin, and -8.0 ± 2.6% in the non-AIA
group and 7.7 ± 2.8% in the AIA group after addition
of 10−4 M aspirin (Fig. 4). These results demon-
strated that CD11b expression on eosinophils from
AIA patients was significantly increased from the
baseline by aspirin stimulation (p < 0.05). However,
intriguingly, aspirin stimulation significantly de-
creased the CD11b on eosinophils from non-AIA pa-
tients. A representative flowcytometric data of aspirin-
induced enhancement of CD11b on eosinophils from
an AIA patient was shown in Figure 2c, d.
EFFECTS OF PGE2 ADDITION ON THE ASPIRIN-
INDUCED INCREASE OF CD11b EXPRESSION
The increase of CD11b expression on the eosinophils
induced by 10−4 M aspirin in the AIA group tended to
be inhibited by the addition of PGE2, in a
concentration-dependent manner (0.2 ± 2.9% at 10−7
Isogai S et al.
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Fig.　2　Flowcytometric analysis of CD11b expression on eosinophils. PMNs from a non-AIA 
patient were double stained with anti-CD16 and anti-CD11b (a). The eosinophil fraction (CD16-
negative) was separated from neutrophil fraction (CD16-positive) using fl ow cytometry (b). PMNs 
from an AIA patient under the aspirin stimulation were stained with anti-CD16 and anti-CD11b (c). 
The eosinophil fraction from an AIA patient increased CD11b expression by the stimulation of 
aspirin (10−4 M) (d). Data are representative of three independent experiments.
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Fig.　3　Comparison of the CD11b expression on eosino-
phils in the aspirin non-stimulated condition (control) mea-
sured by mean fl uorescence intensity (MFI) when stained 
with FITC-anti CD11b antibody. CD11b expression in the 
non-stimulated state was 147.3 ± 12.1 in the non-AIA group 
and 130.4 ± 4.7 in the AIA group; the difference between the 
2 groups was not signifi cant. Columns and vertical bars rep-
resent the mean ± SE.
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M, -0.6 ± 2.9% at 10−6 M, and -3.5 ± 4.0% at 10−5 of
PGE2; a tendency toward a significant difference (p =
0.07) was seen after the addition of 10−5 M as com-
pared with the value seen in the absence of addition
of PGE2 [5.2 ± 2.4%]). No obvious differences were
observed in the non-AIA group (Fig. 5).
POSSIBILITY OF in vitro DIAGNOSIS OF AIA US-
ING ASPIRIN-INDUCED CD11b EXPRESSION
LEVEL ON THE PERIPHERAL BLOOD EOSINO-
PHILS AS AN INDICATOR
When cases showing increase of CD11b expression
on the peripheral blood eosinophils after the addition
of 10−4 M aspirin were regarded as positive, 19 out of
20 patients were assessed as positive in the AIA
group (sensitivity 95.0%) and only 1 out of 19 patients
was assessed as positive in the non-AIA group (speci-
ficity 94.7%) (Fig. 6).
DISCUSSION
AIA is an important condition that should always be
borne in mind when treating patients with bronchial
asthma. In regard to the mechanism of its onset, inhi-
CD11b for Diagnosis of AIA
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Fig.　4　Effects of aspirin (10−7 M to 10−4 M) on the CD11b expression of eosino-
phils. Eosinophils from AIA patients or non-AIA patients were stimulated with aspi-
rin at various concentrations (10−4 M-10−7 M), followed by assessment of CD11b 
expression by fl owcytometer. With aspirin stimulation, CD11b expression level on 
eosinophils from AIA patients signifi cantly increased from the baseline (non-
stimulated condition), while it signifi cantly decreased on the eosinophils from non-
AIA patients. Columns and vertical bars represent the mean ± SE. *p < 0.05 com-
pared to the non-stimulated baseline.
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bition of COX in the pathway of arachidonic acid me-
tabolism by NSAIDs is believed to play a major role.
With regard to the arachidonic acid metabolites most
closely involved in the pathology of AIA, there have
been reports of elevated leukotriene E4 (LTE4) levels
in the urine5,6 and elevated topical PGE2 levels in the
airways5,7 in AIA patients in a stable clinical state as
compared with those in non-AIA patients. Also, fol-
lowing exposure to NSAIDs, the LTE4 levels in the
urine8-10 and topical pLT levels in the airways9,10 re-
portedly increase and the topical PGE2 levels in the
airways decrease significantly.9
The NSAID challenge tests for the diagnosis of AIA
include systemic challenge tests and local challenge
tests. The systemic challenge tests can be conducted
by oral or intravenous administration. Being a sys-
temic test, it is more reliable and symptoms outside
of the airways can also be identified; however, the in-
duced symptoms may become severe, increasing the
risk levels of the tests.
The intravenous test can no longer be performed in
Japan, because marketing of the reagent for the test,
lysine-aspirin, has been discontinued here. Bronchial
inhalation is used for local challenge tests; however,
this approach is not necessarily ideal because only lo-
cal symptoms can be identified, and often, pseudo-
negative results are obtained. The standard approach
used at present is the oral aspirin challenge test.
However, challenge tests are associated with the
risk of developing severe symptoms, and an in vitro
method of diagnosis has been awaited. Several at-
tempts have been made to develop methods for in vi-
tro diagnosis of AIA, and approaches based on pLT
production, 15-HETE production11 and lipoxin pro-
duction12 in the peripheral blood PMNs as indicators
have been examined. However, adequate follow-up
and verification have not been conducted, and their
usefulness remains questionable. Therefore, the po-
tential usefulness of a method using the adhesion
molecule CD11b expressed on the cell surface of
eosinophils as a marker for the in vitro diagnosis of
AIA was examined in this study.
CD11b is an adhesion molecule associated with lo-
cal accumulation of eosinophils in the airways and is
regarded as an indicator of activation of granulocytes.
The expression level of this molecule increases fol-
lowing stimulation of the cells by various factors such
as interleukin (IL)-4 and IL-5 and platelet activating
Isogai S et al.
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Fig.　5　Effects of PGE2 on the CD11b expression on eosinophils induced 
by aspirin. The increase of CD11b expression induced by 10−4 M aspirin on 
the eosinophils from AIA patients was inhibited by the addition of PGE2, in 
a concentration-dependent manner. No obvious differences were observed 
in the non-AIA group. Columns and vertical bars represent the mean ± SE.
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Fig.　6　Rate of changes in the CD11b expression induced 
by aspirin (10−4 M) on eosinophils may be useful for in-vitro 
diagnosis of AIA. When cases showing increase of CD11b 
expression of eosinophils by 10−4 M aspirin were regarded 
as positive, 19 out of 20 patients were assessed as positive 
in the AIA group (sensitivity 95.0%) and only 1 out of 19 pa-
tients was assessed as positive in the non-AIA group (speci-
fi city 94.7%). Bars indicate the mean ± SD.
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factor (PAF).13-15 There have been no reports on the
relationship between NSAID stimulation and CD11b
expression on the eosinophils in AIA. Although stud-
ies on the gastrointestinal system have shown that as-
pirin and indomethacin up-regulated CD11b expres-
sion andor increased its adhesion to the endothelial
cells,16,17 the cells evaluated were neutrophils, and no
examination of eosinophils has been conducted.
Measurement of CD11b expression by flowcytome-
try in this study enabled differentiation between an
AIA group and non-AIA group. In other words, the
CD11b expression level increased on the eosinophils
of AIA patients after the addition of aspirin but de-
creased on the cells of the non-AIA patients, with a
significant difference observed between the 2 groups.
Moreover, the aspirin-induced increase of CD11b ex-
pression on the peripheral blood eosinophils of pa-
tients with AIA was no longer seen after the addition
of PGE2. These findings suggest that decrease of
PGE2 production may be involved in the aspirin-
induced increase of CD11b expression on eosino-
phils.
When cases showing increased CD11b following
exposure to NSAIDs were regarded as positive, 19
out of the 20 patients with AIA were assessed as posi-
tive (sensitivity 95.0%), whereas only 1 out of the 19
patients in the non-AIA group were assessed as posi-
tive (specificity 94.7%). For the diagnosis of AIA, it is
inevitable at present to depend on the history and in
vivo NSAIDs challenge tests. Although our method
requires flowcytometry, it could become applicable as
a method for in vitro diagnosis of AIA in the clinical
setting if the procedure can be made simpler.
CD11b for Diagnosis of AIA
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In conclusion, increase of CD11b expression on
the surface of peripheral blood eosinophils of AIA pa-
tients was observed following the addition of aspirin.
This may become applicable as a simple test in the
clinical setting for in vitro diagnosis of AIA. Suppres-
sion of PGE2 in AIA patients might be involved in
regulation of CD11b expression on eosinophils by as-
pirin administration.
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